1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding, D.A., Chan, G., DeWolf, W.E., Fosberry, A.P., Janson, C.A., Jaworski, D.D., McManus, E., Miller, W.H., Moore, T.D., Payne, D.J., Qiu, X., Rittenhouse, S.F., Slater-Radosti, C., Smith, W., Takata, D.T., Vaidya, K.S., Yuan, C.C., Huffman, W.F.(2001) Bioorg Med Chem Lett 11: 2061-2065
- PubMed: 11514139
- DOI: https://doi.org/10.1016/s0960-894x(01)00404-8
- Primary Citation of Related Structures:
1I2Z - PubMed Abstract:
1,4-Disubstituted imidazole inhibitors of Staphylococcus aureus and Escherichia coli enoyl acyl carrier protein reductase (FabI) have been identified. Crystal structure data shows the inhibitor 1 bound in the enzyme active site of E. coli FabI.
Organizational Affiliation:
GlaxoSmithKline Pharmaceuticals, Antibacterials and Host Defense, 1250 S. Collegeville Road, Collegeville, PA 19426, USA. dirk_a_heerding@sbphrd.com